We believe that fingerprinting the immune system can be a game-changer when it comes to improving the surgical journey for millions of patients. Combining innovative technologies with artificial intelligence, our multidisciplinary team of clinicians, engineers and scientists is focused on holistically improving the standard-of-care. Predicting the risk for complications before surgery is critical to allow personalization of pre-operative clinical interventions, surgical decision-making and improvement of surgical outcomes. 30% of major surgeries result in complications within 30 days postoperatively, such as infection or pneumonia, and even death. Surge is grounded in more than seven years of clinical, basic science, and translational research led by our team at Stanford University. Our test combines single-cell assessment of the immune system before surgery with clinical data available through Electronic Health Records (EHR) using a proprietary machine learning algorithm. Individual immune systems are comprehensively assessed from a single blood sample obtained before surgery and analyzed using mass cytometry. Our method allows us to mimic surgical trauma in a test tube with a small amount of blood containing millions of immune cells before surgery. We use this technique to understand exactly how every immune cell in your body is responding to the trauma to precisely predict postoperative outcomes.
Employees: 1-10
Total raised: $10.69M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 05.10.2025 | Hardware C... | hcvc.co |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2024 | - | $8.09M | - |
| 26.09.2022 | - | $2.6M | - |
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Julien | Hédou | - | linkedin.c... | - | - | United Sta... |
| - | Grégoire | Bellan | - | linkedin.c... | - | g*********... | - |
Mentions in press and media 7
| Date | Title | Description |
| 28.03.2024 | Paris-based Surge gets €7.5M to decrypt immune system and accelerate precision medicine | Read this article in: Paris-based Surge, a company specialised in high-dimensional immune system analysis, announced on Thursday that it has secured €7.5M in a fresh funding round. The funding round was led by Eurazeo with the participation... |
| 28.03.2024 | Surge Closes €7.5M Funding Round | Surge, a Paris, France-based company which specializes in high-dimensional immune system analysis combined with artificial intelligence, raised €7.5M in funding. The round was led by Eurazeo with the participation of Kima, Teampact, and MH ... |
| 26.09.2022 | Surge raises $2.6M to predict surgery complications from a blood test | The company also entered into an exclusive licensing agreement with Stanford There are nearly 6.1 million and 5.1 million abdominal surgeries conducted each year in the United States and Europe, respectively, and approximately 30% result in... |
| 26.09.2022 | Surge Raises €2.5M in Funding | Surge, a San Francisco, CA- and Paris, France-based biotech and medical AI company, raised €2.5M in funding. The round was led by HCVC, with participation from Boutique Venture, and Nicolas Godin. The company intends to use the funds to fur... |
| 22.09.2022 | Making surgeries safer, French biotech Surge raises $2.6 million | French biotech and medical AI platform Surge has raised $2.6 million in funding to decode a patient’s immune system from a blood sample. The pre-seed round was co-led by HCVC and Boutique Venture Partners. Veteran angel investors, including... |
| 22.09.2022 | Surge Raises $2.6M for Blood Test to Predict Post-Surgery Complications | What You Should Know: |
| - | Surge | “PreCyte integrates high-resolution immune system exploration with predictive information to develop preventive strategies, treatments, medical devices.” |